Top

Published in:

Open Access 01-11-2014 | Breast Oncology

Intraoperative Radiation Therapy: A Critical Analysis of the ELIOT and TARGIT Trials. Part 1—ELIOT

Authors: Melvin J. Silverstein, MD, Gerd Fastner, MD, Sergio Maluta, MD, Roland Reitsamer, MD, Donald A. Goer, PhD, Frank Vicini, MD, David Wazer, MD

Published in: Annals of Surgical Oncology | Issue 12/2014

Abstract

Introduction

Two randomized intraoperative radiation therapy trials for early-stage breast cancer were recently published. The ELIOT Trial used electrons (IOERT), and the TARGIT-A Trial Update used 50-kV X-rays (IORT). These studies were compared for similarities and differences. The results were analyzed and used to determine which patients might be suitable for single-dose treatment.

Method

The primary sources of data were the ELIOT Trial and TARGIT-A Trial, as well as a comprehensive analysis of the peer-reviewed literature of accelerated partial breast irradiation (APBI) using 50-kV X-rays or electrons. Studies published or presented prior to March 2014 were analyzed for efficacy, patient restrictions, complications, and outcome.

Results

With a median follow-up of 5.8 years, the 5-year recurrence rates for ELIOT versus external beam radiation therapy (EBRT) patients were 4.4 % and 0.4 %, respectively, p = .0001. A low-risk ELIOT group was identified with a 5-year recurrence rate of 1.5 %. With a median follow-up of 29 months, the 5-year recurrence rates for the TARGIT-A versus EBRT patients were 3.3 % and 1.3 %, respectively, p = .042.

Conclusion

With 5.8 years of median follow-up, IOERT appears to have a subset of low-risk women for whom IOERT is acceptable. With 29 months of median follow-up the results of IORT with 50-kV devices are promising, but longer follow-up data are required. At the current time, single-fraction IOERT or IORT patients should be treated under strict institutional protocols.

Athas W, Adams-Cameron M, Hunt WC, Amir-Fazli A, Key C. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst. 2000;92:269–71.PubMedCrossRef

Ballard-Barbash R, Potosky A, Harlan L, Nayfield S, Kessler L. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst. 1996;88:716–26.PubMedCrossRef

Polgar C, Fodor J, Tibor M, Sulyok Z, Hasler M. Breast-conserving therapy with partial or whole breast radiation: Ten-year results of the Budapest randomized trial. Radiother Oncol. 2013;108:197–202.PubMedCrossRef

Shah C, Badiyan S, Wilkinson J, Vicini F, Beitsch P, Keisch M, et al. Treatment efficacy with accelerated partial breast irradiation (APBI): final analysis of the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial. Ann Surg Oncol. 2013;20:3279–85.PubMedCrossRef

Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomized controlled equivalence trial. Lancet Oncol. 2013;14:1269–77.PubMedCrossRef

Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010;376:91–102.PubMedCrossRef

Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomized trial. Lancet. 2013;383:603–13.PubMedCrossRef

Veronesi U, Gatti G, Luini A, Intra M, Orecchia R, Borgen P, et al. Intraoperative radiation therapy for breast cancer: technical notes. Breast J. 2003;9:106–12.PubMedCrossRef

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.PubMedCrossRefPubMedCentral

10.

Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382–7.PubMedCrossRefPubMedCentral

11.

Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg. 2009;209:269–77.PubMedCrossRef

12.

Orecchia R, Leonardi M, Maisonneuve P, Morra A, Lazzari R, Cattani F, et al. Intraoperative Radiotherapy with electrons (ELIOT) for early breast cancer: the European Institute of Oncology experience. Transl Cancer Res. 2014;3:59–64.

13.

Leonardi MC, Maisonneuve P, Mastropasqua MG, Morra A, Lazzari R, Dell’Acqua V, et al. Accelerated partial breast irradiation with intraoperative electrons: Using GEC-ESTRO recommendations as guidance for patient selection. Radiother Oncol. 2013;106:21–7.

14.

Leonardi MC, Maisonneuve P, Mastropasqua MG, Morra A, Lazzari R, Rotmensz N, et al. How do the ASTRO consensus statement guidelines for the application of accelerated partial breast irradiation fit intraoperative radiotherapy? A retrospective analysis of patients treated at the European Institute of Oncology. Int J Radiat Oncol Biol Phys. 2012;83:806–13.PubMedCrossRef

15.

Polgár C, Van Limbergen E, Pötter R, Kovács G, Polo A, Lyczek J, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence. Radiother Oncol. 2010;94:264–73.PubMedCrossRef

16.

Maluta S, Dall’Oglio S, Marciai N, Gabbani M, Franchini Z, Pietrarota P, et al. Accelerated partial breast irradiation using only intraoperative electron radiation therapy in early stage breast cancer. Int J Radiat Oncol Biol Phys. 2012;84:e145–52.PubMedCrossRef

17.

Maluta S, Dall’Oglio S, Goer D, Marcial N. Intraoperative electron radiotherapy (IOERT) as an alternative to standard whole breast irradiation: only for low-risk subgroups? Breast Care (Basel). 2014;9:102–6.CrossRef

18.

Krechetov S, Goer D. Effective Treatment Volume of the Small Size IORT Applicators. Paper presented at: American Association of Physicists in Medicine. July 20–24, 2014; Austin, TX.

19.

Veronesi U, Orecchia R, Luini A, Galimberti V, Zurrida S, Intra M, et al. Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res Treat. 2010;124:141–51.PubMedCrossRef

20.

Surgeons TASoB. Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer. The American Society of Breast Surgeons, 2011. https://www.breastsurgeons.org/statements/PDF_Statements/Axillary_Management.pdf.

21.

Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426–32.PubMed

22.

Veronesi U. The Paradigm of Early Breast Cancer: Opportunities for IORT. Paper presented at: ISIORT 2008, International Society of Intraoperative Radiation Therapy, June 11, 2014, Madrid, Spain.

23.

Jobsen J, van der Palen J, Ong F, Meerwaldt J. The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. Int J Radiat Oncol Biol Phys. 2003;57:724–31.PubMedCrossRef

24.

Goer D, Silverstein MJ. The emerging role of intraoperative radiation therapy (IORT) in breast cancer. In: Riker A, Krueger B (eds) Breast disease: comprehensive management. New York, Heidelberg, London: Springer Science; 2014.

Title: Intraoperative Radiation Therapy: A Critical Analysis of the ELIOT and TARGIT Trials. Part 1—ELIOT
Authors: Melvin J. Silverstein, MD
Gerd Fastner, MD
Sergio Maluta, MD
Roland Reitsamer, MD
Donald A. Goer, PhD
Frank Vicini, MD
David Wazer, MD
Publication date: 01-11-2014
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 12/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-014-3998-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Intraoperative Radiation Therapy: A Critical Analysis of the ELIOT and TARGIT Trials. Part 1—ELIOT

Abstract

Introduction

Method

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2014

A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio for Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy

A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a Granulocyte–Macrophage Colony Stimulating Factor–Producing Bystander Cell Line in Patients with Metastatic Colorectal Cancer

Epithelial to Mesenchymal Transition Expression Profiles as Predictive Biomarkers of Recurrence Following Resection of HCC: Implications for Current Clinical Use and Future Stratification for Systemic Therapy

Current Trends in the Management of Malignant Peritoneal Mesothelioma

Choosing a Cancer Surgeon: Analyzing Factors in Patient Decision Making Using a Best–Worst Scaling Methodology

The Hanging Maneuver Facilitates Laparoscopic Right Hepatectomy